PPLPHARMA Piramal Pharma Ltd Expansion Plans Announcement 2024 - Q2 FY25 Results Piramal Pharma Ltd announced its Q2 and H1 FY25 financial results, showing a revenue growth of 17% YoY at ₹2,242 crore for Q2 and an EBITDA increase of 28% YoY, with an EBITDA margin of 18%. The company also revealed an $80 million expansion plan for its Lexington facility, expected to be completed by FY27, as part of its growth strategy towards achieving $2 billion revenue with a 25% EBITDA margin by FY30..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Piramal Pharma Ltd